REFERENCES
- Alexanian R, Haut A, Khan A, et al. Treatment for mul-tiple myeloma: Combination chemotherapy with different mel-phalan dose regimens. JAMA 1969; 208: 1680–5.
- McLaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 1982; 60: 851–5.
- Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32: 20–30.
- Barb o B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–6.
- Logassy G, Shapira A. A prospective cohort study of effect of vincristine on audition. Anticancer Drugs 1996; 7: 525–6.
- Logassy G, Shapiro A. Sensorineural hearing loss asso-ciated with vincristine treatment. Blut 1990; 61: 320.
- Yousif H, Richardson SG, Sounders WA. Partially reversible nerve deafness due to vincristine. Postgrad Med J 1990; 66: 688–9.
- Serafy A. The effects of vincristine sulfate on the neuro-logical elements of the rabbit cochlea. J Laryngol Otol 1981; 95: 49–54.
- Mahajan SL, Ikeda Y, Myers TJ, Baldini MG. Acute acoustic nerve palsy associated with vincristine therapy. Cancer 1981; 47: 2404–6.